<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04516707</url>
  </required_header>
  <id_info>
    <org_study_id>ICM-URC 2015/75</org_study_id>
    <nct_id>NCT04516707</nct_id>
  </id_info>
  <brief_title>Evaluation of Tolerance and Efficacy Retrospective Data of XOFIGO</brief_title>
  <acronym>XOFIGO</acronym>
  <official_title>Evaluation of Tolerance and Efficacy Retrospective Data of XOFIGO Prescribed by AMM in Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut du Cancer de Montpellier - Val d'Aurelle</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since 13 November 2013, XOFIGO has been authorised on the European zone for the treatment of&#xD;
      patients with prostate cancer, in the phase of resistance to castration, with symptomatic&#xD;
      bone metastases.&#xD;
&#xD;
      bone metastases frequently give rise to &quot;bone events&quot; that include spinal cord compressions&#xD;
      and pathological fractures requiring surgery or external radiotherapy.&#xD;
&#xD;
      Bone metastases are an important cause of death, disability, quality of life degradation and&#xD;
      increase the cost of treatment.&#xD;
&#xD;
      Xofigo is indicated in patients with bone metastases symptomatic of hormone-resistant&#xD;
      prostate cancer and without known visceral metastases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Since 13 November 2013, XOFIGO has been authorised on the European zone for the treatment of&#xD;
      patients with prostate cancer, in the phase of resistance to castration, with symptomatic&#xD;
      bone metastases. Prostate cancer is the most common non-cutaneous cancer in men&#xD;
      internationally, and more than 90% of patients with hormone-resistant prostate cancer will&#xD;
      have bone metastases.&#xD;
&#xD;
      They frequently give rise to &quot;bone events&quot; that include spinal cord compressions and&#xD;
      pathological fractures requiring surgery or external radiotherapy.&#xD;
&#xD;
      Bone metastases are an important cause of death, disability, quality of life degradation and&#xD;
      increase the cost of treatment.&#xD;
&#xD;
      There is therefore a need for bone-targeting therapeutic agents that provide a benefit in&#xD;
      terms of survival.&#xD;
&#xD;
      Xofigo is indicated in patients with bone metastases symptomatic of hormone-resistant&#xD;
      prostate cancer and without known visceral metastases.&#xD;
&#xD;
      This treatment appears to have fewer side effects than chemotherapy (and does not call into&#xD;
      question subsequent chemotherapy) or that the currently available metabolic bone radiotherapy&#xD;
      as well as better pain control and survival gain than the latter do not&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Actual">May 1, 2018</completion_date>
  <primary_completion_date type="Actual">January 1, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the epidemiological characteristics of the treated patient population</measure>
    <time_frame>during the treatment of XOFIGO an average of 24 weeks</time_frame>
    <description>clinical data collection in the medical record</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the presence of adverse events resulting from short-term and medium-term XOFIGO treatment</measure>
    <time_frame>during the treatment of XOFIGO an average of 24 weeks</time_frame>
    <description>clinical data collection in the medical record</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the number of patients who were able to benefit from the complete treatment (6 cycles)</measure>
    <time_frame>during the treatment of XOFIGO an average of 24 weeks</time_frame>
    <description>clinical data collection in the medical record</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Collect the causes of premature discontinuation of treatment</measure>
    <time_frame>during the treatment of XOFIGO an average of 24 weeks</time_frame>
    <description>clinical data collection in the medical record</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assess the antalgic effet of treatment (number of antalgic taken and how many time)</measure>
    <time_frame>during the treatment of XOFIGO an average of 24 weeks</time_frame>
    <description>clinical data collection in the medical record</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assess the overall survival</measure>
    <time_frame>during the treatment of XOFIGO an average of 24 weeks</time_frame>
    <description>clinical data collection in the medical record</description>
  </secondary_outcome>
  <enrollment type="Actual">67</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Bone Metastases</condition>
  <condition>Hormone-resistant Prostate Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>clinical database</intervention_name>
    <description>The various clinicam database will be collected solely to meet the objectives of the study.&#xD;
All data collected to create the database for this project will be anonymized</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients who received treatment with XOFIGO in the framework of the AMM, in France&#xD;
        since November 2013 are potentially eligible.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All patients who received treatment with XOFIGO in the framework of the AMM, in France&#xD;
        since November 2013 are potentially eligible.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients expressing a refusal to use this research data&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanuel DESHAYES, MD</last_name>
    <role>Study Chair</role>
    <affiliation>ICM Val d'Aurelle</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icm Val D'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <state>Herault</state>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UP Clermont Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IPC Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRLC de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP Hopital Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ONCOLOPE</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Harrison MR, Wong TZ, Armstrong AJ, George DJ. Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Manag Res. 2013;5:1-14. doi: 10.2147/CMAR.S25537. Epub 2013 Jan 8.</citation>
    <PMID>23326203</PMID>
  </results_reference>
  <results_reference>
    <citation>Nilsson S, Strang P, Aksnes AK, Franzèn L, Olivier P, Pecking A, Staffurth J, Vasanthan S, Andersson C, Bruland ØS. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer. 2012 Mar;48(5):678-86. doi: 10.1016/j.ejca.2011.12.023. Epub 2012 Feb 15. Review.</citation>
    <PMID>22341993</PMID>
  </results_reference>
  <results_reference>
    <citation>Parker CC, Pascoe S, Chodacki A, O'Sullivan JM, Germá JR, O'Bryan-Tear CG, Haider T, Hoskin P. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol. 2013 Feb;63(2):189-97. doi: 10.1016/j.eururo.2012.09.008. Epub 2012 Sep 13.</citation>
    <PMID>23000088</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 12, 2020</study_first_submitted>
  <study_first_submitted_qc>August 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2020</study_first_posted>
  <last_update_submitted>August 14, 2020</last_update_submitted>
  <last_update_submitted_qc>August 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>xofigo</keyword>
  <keyword>clinical database</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

